Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care (POC). The Accula™ System is a CLIA Waived sample-to-answer platform comprised of a palm-sized dock with single-use cassettes for Flu A/B and RSV. This patented system provides actionable, laboratory-quality results at POC with greater sensitivity and specificity than current infectious disease rapid immunoassay tests. The Accula Flu A/Flu B and the Accula RSV tests have obtained CE Mark in the EU and 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waiver from the US Food and Drug Administration (FDA). Both products are distributed in the US by Sekisui Diagnostics under the Silaris™ brand. Mesa Biotech has secured a number of strategic agreements for distribution in Europe and Asia. For more information visit http://www.mesabiotech.com.